C&R Research Subsidiary Q-fitter Selected as ‘Collaborative First Step Project’ by Ministry of SMEs and Startups
Targets to Launch ‘Web-based Drug Development Matching Market Platform’ by End of 2019
Seoul, Korea, March 20, 2019 — Q-fitter (CEO Moon Tae Yoon), a subsidiary of C&R Research, has been selected as the supervising organization for the industry-academia collaborative technology development project (first step) conducted by the Ministry of SMEs and Startups (MSS).
Q-fitter is currently analyzing the service strengths of its partner companies in the Korean pharmaceutical industry. The purpose of the analysis is to develop Korea’s first ‘web-based drug development matching market platform service’ in collaboration with the clinical pharmacology department of the Catholic University of Korea – Industry-academic Cooperation Foundation.
“We are planning to develop approximately 4,000 items that cover the entire process of drug development within the first quarter of 2019 and use them in the survey to check the actual service scope of our partners,” a company official announced.
‘Web-based drug development matching market platform’ is a service area that has not been easily approached in the world before. Q-fitter expects that the platform will help match companies with a candidate drug with a team of professionals once it is established. It is also expected that Q-fitter will help establish the partner companies’ business development strategies by providing easy access to a potential customer base.
The service will be provided free of charge for all corporate registration and matching services for one year after development. The company plans to increase satisfaction and reliability by collecting and incorporating feedback from developers and partners who used the service during the beta test service period.
Director of the project and Q-fitter Byung Jin Ahn stated, “The ‘web-based drug development matching market platform,’ which is currently under development, will deliver a visualized list of the most suitable partners to the drug development companies through a simple Q&A. The platform is going to be as objective and as fair as possible because the service will be conducted to allow the developer itself to make the final decision of the partner company.”